Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirfenidone + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Tao Zhang
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pirfenidone + PD-1 inhibitor is an investigational combination therapy being evaluated for the treatment of advanced, refractory proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer. This regimen combines pirfenidone, a small molecule anti-fibrotic agent, with a programmed cell death protein 1 (PD-1) inhibitor. The rationale behind this combination is that pirfenidone can remodel the immunosuppressive tumor microenvironment, particularly in patients with liver metastases, by reducing fibrosis and potentially converting immunologically "cold" MSS tumors into "hot" tumors that are more responsive to immune checkpoint blockade. This combination is currently being studied in Phase II clinical trials (e.g., NCT06484153) led by researchers at Union Hospital, Tongji Medical College, often in conjunction with hypofractionated radiotherapy.
- Other names
- pirfenidone and PD-1 monoclonal antibodypirfenidone and PD-1 inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)Transforming growth factor beta 1 (TGF-β1) signaling axis
Beyond the preview
Go deeper on pirfenidone + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirfenidone + PD-1 inhibitor.